Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

Randomized, Double Blind, Parallel Group, Repeat Dose Pharmacokinetic and Pharmacodynamic Study of Four Doses of ATL-962 (40mg, 80mg, 120mg 240mg) in Otherwise-Healthy Obese Volunteers

The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese

Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.

Inclusion Criteria:

• Obese, otherwise-healthy subjects
• Body mass index 30-45kg/m2

Exclusion Criteria:

• Women who are pregnant or breast feeding
• Any drug treatment within 2 weeks of commencement of dosing in this study